Advertisement
(Logo: http://www.newscom.com/cgi-bin/prnh/20080424/NETH117LOGO )
Brian Ennis, President and CEO of ETEX Corporation, states, "ETEX isexcited to offer surgeons a best-in-class combination product that providesoptimal osteoinductive and osteoconductive performance. The market demands acombination DBM product that not only flows but sets hard for a completedefect fill. This product is the culmination of years of research anddevelopment. Based on initial customer feedback, we anticipate a robust marketresponse."
Advertisement
EquivaBone(TM) is a proprietary combination of osteoinductiveDemineralized Bone Matrix (DBM) and ETEX's osteoconductive nanocrystallinecalcium phosphate. ETEX is proud to offer the first combination product thatis both moldable and injectable and sets hard once implanted. In addition,osteoinductivity of the DBM is certified after sterilization, by lot, for theentirety of shelf life.
Both trauma and spine fusion data were included in the 510k submissionwhich received FDA clearance on April 28, 2008. EquivaBone(TM) is intended foruse in filling bone voids or defects of the skeletal system (includingextremities, pelvis, and spine) that are not intrinsic to the stability of thebone structure.
ETEX will market EquivaBone(TM) through its direct distribution channel.
About ETEX Corporation
Established in 1989, ETEX Corporation develops, manufactures andcommercializes calcium phosphate-based biomaterials for improved orthopedicclinical outcomes. A leader in bioresorbable bone substitute materials, ETEXfocuses on expanding applications through combinations with cells, biologics,or therapeutic agents delivered in minimally invasive and easy to use systems.For more information, visit www.etexcorp.com.
SOURCE ETEX Corporation
